Aberrant hydroxymethylation in promoter CpG regions of genes related to the cell cycle and apoptosis characterizes advanced chronic myeloid leukemia disease, poor imatinib respondents and poor survival

Table 7 Achievement of molecular response

Time duration After initiation of Treatment (months)	Response	Imatinib 400-mg OD dose group (n = 59)	Imatinib 800-mg OD dose group (n = 91)	Total proportion of patients (n = 150)
6 months	*MMR n(%)	7 (11.86)	12 (13.18)	19 (12.66)
12 months	*MMR n(%)	17 (28.81)	34 (37.36)	51 (34.00)
6 months	*MR⁴ n(%)	4 (6.78)	5 (5.49)	9 (6.00)
12 months	*MR⁴ n(%)	8 (13.56)	14 (15.38)	22 (14.66)
6 months	*MR^4.5 n(%)	3 (5.08)	5(5.49)	8 (5.33)
12 months	*MR^4.5 n(%)	7 (11.86)	11 (12.08)	18 (12.00)

^* 23 CML patients failed to achieve molecular response out of which 17 had primary failure and 6 had secondary failure

ISSN: 1471-2407